Annovis Bio (ANVS) Projected to Announce Quarterly Earnings on Wednesday

Annovis Bio (NYSE:ANVS) will likely be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Annovis Bio to announce earnings of ($0.30) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Annovis Bio (NYSE:ANVS) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. On average, analysts expect Annovis Bio to post ($1.32) EPS for the current fiscal year and ($0.54) EPS for the next fiscal year.

Annovis Bio Stock Performance

ANVS stock opened at $1.09 on Wednesday. The firm has a market cap of $46.73 million, a PE ratio of -0.61 and a beta of 1.36. The firm’s fifty day moving average is $1.23 and its 200 day moving average is $1.91. Annovis Bio has a one year low of $0.93 and a one year high of $5.50.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ANVS. Zacks Research upgraded shares of Annovis Bio to a “hold” rating in a research report on Thursday, July 9th. Wall Street Zen lowered Annovis Bio from a “sell” rating to a “strong sell” rating in a research note on Monday, September 28th. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Annovis Bio in a report on Tuesday, August 18th. Roth Capital lowered their price target on Annovis Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, August 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Annovis Bio in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

About Annovis Bio

Annovis Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on therapies designed to address mechanisms associated with neurodegeneration rather than treating only individual symptoms.

Annovis Bio’s lead product candidate is buntanetap, formerly known as ANVS401. Buntanetap is an orally administered small molecule being investigated for its potential to reduce the production of multiple neurotoxic proteins linked to neurodegenerative disorders.